J.Jpn. Surg. Soc.. 91(9): 1356-1359, 1990

---

Report on the annual meeting

EFFECT OF MULTIMODALITY THERAPY ON SURVIVAL IN RESECTED SMALL CELL AND NON-SMALL CELL LUNG CANCER

Reviewing the outcome of 637 resected lung cancer patients, we attempted to clarify the benefit of multimodality therapy on survival. There were 37 patients with small cell lung cancer (SCLC) and 600 with non-small cell lung cancer (non-SCLC). Of 37 patients with SCLC, 36 received adjuvant chemotherapy. The overall 5-year survival rate was 38%, which was better than those (1-12%) without adjuvant chemotherapy, reported by other investigators. However, long-term survivors were generally observed only in stages I and II patients. To improve survival rate for resected stage III, preoperative chemotherapy has been recently introduced in the management of SCLC. Survival for stage III patients appears to be prolonged by this treatment modality. On the other hand, overall 5-year survival rate for 600 resected non-SCLC was 47%. This is improving year by year, showing 30% at 5 years before 1970, 39% between 1971 and 1980, and 56% between 1981 and 1988, respectively. We have studied the beneficial effects of cisplatin-based polychemotherapy and immunotherapy (N-CWS) on resected lung cancer in randomized trial. However, there was no evidence of improved survival and delaying recurrence in two trials.
In conclusion, we consider that multimodality therapy consisting of surgery, chemotherapy, immunotherapy and radiotherapy play the important role on recent improved survival of resected lung cancer patlents.

---

---

To read the PDF file you will need Adobe Reader installed on your computer.